MC# 22-27 - A Phase I, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer

  • Agent(s): JANX007
  • Disease Type(s): Prostate
  • Phase(s): I
  • Drug Classification(s): Immunotherapy, Targeted Therapy
  • Molecular Target(s): PSMA

Mechanism of Action

JANX007 is a Tumor Activated T Cell Engager therapeutic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer.


In this study, the sponsor and investigators want to learn:

  • How much of JANX007 can be given with an acceptable level of side effects
  • The effects of JANX007 (good and bad) 
  • How much of JANX007 is absorbed into the blood and how fast it is removed
  • If the body’s immune system has a response to JANX007
Inclusion Criteria
  1. Male subjects ≥18 years of age at the time of signing informed consent
  2. Histologically or cytologically confirmed adenocarcinoma of the prostate
  3. Progressive mCRPC or intolerance to the most recent therapy
  4. PSMA expressing tumor
  5. Adequate organ function
Exclusion Criteria
  1. Prior solid organ transplant
  2. Prior treatment with PSMA-targeted CAR-T cell therapy
  3. Clinically significant cardiovascular disease
  4. HIV or acute/chronic hepatitis C infection
  5. Any medical condition or clinical laboratory abnormality likely to interfere with assessment of safety or efficacy of study treatment


  • Dallas, TX - Mary Crowley Cancer Research - Medical City
More Info:

Contact Us About This Trial

Reach out to us by sharing your info in the form below or give us a call at 972-566-3000.

Re: MC# 22-27